Orchestra BioMed announced that its Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) will be presented at the TCT 2026 conference, highlighting its unique method of delivering sirolimus directly into the vessel wall for treating coronary in-stent restenosis. The Virtue Trial, a randomized controlled study comparing Virtue SAB to a drug-coated balloon, is currently enrolling patients. This technology aims to improve vessel healing and reduce restenosis without adding metal layers, potentially offering a more durable treatment option. The presentation will detail the device's mechanism, supporting clinical data, and trial design, signaling progress toward regulatory approval and wider clinical use.
Orchestra BioMed's Virtue SAB presentation at TCT 2026 is the subject, with Pluang's health sector market data providing context. Of 150 priced health-sector US stocks on Pluang, 91 rose and 53 fell today. Notable movers include LLY at USD 1,350.62 (+4.80%, 29% Sell / 71% Buy, typical hold 94 days), INCY at USD 112.32 (-3.89%, 0% Sell / 100% Buy, typical hold 33 days), and AMGN at USD 468.69 (+3.73%, 18% Sell / 82% Buy, typical hold 73 days). Data is as of Oct 29, 2026 19:12 WIB.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
